Background: Despite considerable efforts, few drugs are available for the treatment of alcohol (ethanol [EtOH]) use disorder (AUD). EtOH directly or indirectly modulates several aspects of the central nervous system, including neurotransmitter/neuromodulator systems. Relapse vulnerability is a challenge for the treatment of EtOH addiction. EtOH withdrawal symptoms create motivational states that lead to compulsive EtOH drinking and relapse even after long periods of abstinence. Among the therapeutics to treat AUD, naltrexone (NTX) is a pharmacological treatment for relapse. The present study evaluated the effect of NTX on EtOH drinking in male and female EtOH-dependent rats during abstinence.
THANOL (ETOH) PRODUCES its effects on the central nervous system through several mechanisms, one of which involves alterations of the endogenous opioid system. Opioid receptor subtypes (l, d, j) have high affinity for 3 main classes of endogenous opioids (b-endorphin, enkephalins, and dynorphins, respectively) . Acute EtOH stimulates the release of b-endorphin, enkephalins, and dynorphin in humans and rats (Dai et al., 2005; Gianoulakis et al., 1996b; Marinelli et al., 2003 Marinelli et al., , 2004 Marinelli et al., , 2005 Marinelli et al., , 2006 Popp and Erickson, 1998; Rasmussen et al., 1998) . Naltrexone (NTX) is an approved medication for the treatment of alcoholism, based on its efficacy in reducing the craving for and consumption of EtOH (Volpicelli et al., 1992) . It is a nonspecific opioid receptor antagonist. In nondependent subjects, the NTX-induced blockade of opioid receptors for these endogenous ligands suppresses EtOH consumption Gonzales and Weiss, 1998; Shoemaker et al., 2002; Stromberg, 2004) , and this beneficial effect is blunted in postdependent subjects (Ji et al., 2008; Sabino et al., 2006 Sabino et al., , 2013 Walker and Koob, 2008) . Although clinical trials have demonstrated the efficacy of NTX in reducing the risk of relapse in heavy drinkers, many patients experience no benefit of treatment (Krystal et al., 2001 ). This suggests that several factors influence treatment success (e.g., the time of intervention during abstinence, gender, and changes in the endogenous opioid system). Numerous investigations have sought to characterize biochemical modifications of the endogenous opioid system that are closely associated with the incidence of alcoholism or alcohol use disorder (AUD). For example, both mice and humans with a high risk of alcoholism present greater hypothalamic b-endorphin activity (Gianoulakis et al., 1996a,b) . Repeated EtOH administration induces both short-and long-term alterations of opioid levels in brain regions that are associated with motivation and reward (e.g., nucleus accumbens; Lindholm et al. 2000) . In rodents, chronic EtOH intake and EtOH withdrawal have been shown to induce a wide range of perturbations of the opioid system, suggesting a putative role for the endogenous opioid system in the effects of EtOH, such as a decrease in l-opioid receptor expression in the nucleus accumbens and dorsal striatum (Turchan et al., 1999) , an increase in prodynorphin mRNA levels in the nucleus accumbens (Przewlocka et al., 1997) , a decrease in j-opioid receptor mRNA expression in the ventral tegmental area and nucleus accumbens (Rosin et al., 1999) , an increase in preproenkephalin mRNA expression in the amygdala, and a decrease in preproenkephalin mRNA expression in the nucleus accumbens (Cowen and Lawrence, 2001) .
Men have been consistently shown to drink more EtOH and have a greater propensity to develop AUD than women. Recent data, however, suggest that EtOH consumption in men and women has become more similar over the past 2 decades (Keyes et al., 2008; Slade et al., 2016) . Several studies have reported sex differences in EtOH intake in rats, in which females drank more than males (Blanchard et al., 1993; Li and Lumeng, 1984; Morales et al., 2015; Priddy et al., 2017; , whereas other studies found no sex differences (van Haaren and Anderson, 1994; Moore and Lynch, 2015; Schramm-Sapyta et al., 2014) . The use of different rat strains (e.g., Wistar, Sprague Dawley, and Long Evans) or different experimental designs (e.g., 2-bottle choice, self-administration, and chronic intermittent EtOH [CIE] vapor exposure) may account for such discrepancies. To our knowledge, no study to date has compared the efficacy of NTX in preventing EtOH drinking between males and females. Such information is especially important when attempting to develop efficient pharmacotherapies for the treatment of AUD.
The resumption of excessive EtOH drinking (i.e., relapse) even long after physical signs of withdrawal have dissipated is a challenge for the successful treatment of AUD. Although NTX is an approved treatment for AUD, it is unclear why treatment efficacy varies between subjects. Therefore, to gain a better understanding of the efficacy of NTX in preventing the recurrence of EtOH drinking during abstinence, the present study systematically tested the effects of NTX at different time points during abstinence in male and female rats.
MATERIALS AND METHODS

Rats
Forty-eight Wistar rats (24 males and 24 females; Charles River, Wilmington, MA), weighing 150 to 175 g upon arrival, were housed 2 per cage in a temperature-and humidity-controlled vivarium on a reverse 12-h/12-h light/dark cycle with ad libitum access to food and water. The animals were given at least 1 week to acclimate to the housing conditions and handling before testing. All of the procedures were conducted in strict adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute.
EtOH Self-Administration Training (Fig. 1) The EtOH self-administration training procedure was a modification of early studies by Wise (1973) and revised by Simms and colleagues (2008) . The procedure did not require any fading (saccharin or sucrose) procedure to initiate voluntary EtOH drinking. On the Monday (Day 1) following the end of the housing acclimatization period, the rats were single-housed and presented with 2 bottles: 1 bottle contained H 2 O, and 1 bottle contained 10% (w/v) EtOH (prepared in tap water from 95% w/v EtOH) for 3 days (Monday, Tuesday, and Wednesday; Days 1 to 3). On Thursday and Friday (Days 4 and 5), the rats were group-housed (2 per cage) and given only H 2 O in their home cage. On Saturday (Day 6), the rats were given access to EtOH self-administration for 12 hours in standard operant conditioning chambers (29 cm 9 24 cm 9 19.5 cm; Med Associates, St. Albans, VT) on a fixed-ratio 1 (FR1) schedule of reinforcement, in which each response at the right active lever (i.e., the only lever available at that time) resulted in the delivery of 0.1 ml of fluid and brief illumination of a cue light (0.5 seconds) above the lever. Food and water were available in the operant chambers during this self-administration session to avoid food or water deprivation because of the extensive length of the operant procedure. Following the 12-hour session, the rats were returned to their home cage. On Sunday (Day 7), they were left undisturbed. On Monday and Tuesday (Days 8 and 9), the rats were given access to EtOH self-administration for 2 h/d and on Wednesday and Thursday (Day 10 and 11) for 1 h/d. Starting on Friday (Day 12) and for the rest of the selfadministration days, the rats underwent 30-minute self-administration sessions with the introduction of a second (left) inactive lever at which responses were recorded but had no programmed consequences. Tail bleeds were performed after each self-administration session during the last 5 days of training, and blood alcohol levels (BALs) were measured (Fig. 1A) . The rats were scored for somatic withdrawal signs (WDS) upon the completion of training (Fig. 1A) .
Chronic Intermittent EtOH Vapor Exposure (Fig. 1) At the end of EtOH self-administration training, 2 rats (1 male and 1 female) did not acquire EtOH self-administration, thus reducing the number of animals to 46. After 21 sessions of EtOH selfadministration, half of the rats (n = 22; 11 males and 11 females) were then made dependent (EtOH postdependent [EtOH PD ]) by CIE vapor exposure. The other half (n = 24; 12 males and 12 females) comprised the nondependent group (EtOH ND ) that was exposed only to air. During 6-week dependence induction, the rats underwent daily cycles of 14 hours ON (BALs during vapor exposure ranged between 150 and 250 mg%, measured with a blood analyzer [GC-headspace; Agilent Technologies, Santa Clara, CA]) and 10 hours OFF and were left undisturbed for 3 weeks except to control their BALs (measured during the last 15 minutes of vapor exposure) and to score WDS (at 8 hours of abstinence) once per week. Behavioral signs of withdrawal were measured by a laboratory assistant who was blind to the experimental conditions using a rating scale that was adapted from an original study by Macey and colleagues (1996) and included ventromedial limb retraction, vocalization (i.e., irritability to touch), tail rigidity, abnormal gait, and body tremors. Each sign was given a score of 0 to 2, based on the following severity scale: 0 = no sign, 1 = moderate, and 2 = severe. The sum of the 5 scores (0 to 10) was used as a quantitative measure of withdrawal severity and to confirm dependence. In this model, rats exhibit somatic and motivational signs of withdrawal (Vendruscolo and Roberts, 2014) . Starting at the beginning of the fourth week of CIE vapor exposure, the rats were subjected to 30-minute FR1 EtOH self-administration sessions when acute abstinence occurred (i.e., 8 hours after the vapor was turned off when brain and BALs were negligible), 3 times per week (Monday, Wednesday, and Friday), in which a gradual increase in EtOH intake should be measured (Vendruscolo and Roberts, 2014) . The air-exposed rats underwent the same procedure.
Effects of NTX on EtOH Self-Administration During Abstinence (Fig. 1) Following 6 weeks of CIE vapor or air exposure, the animals began the abstinence phase and were tested for the effect of NTX hydrochloride (Sigma, St. Louis, MO) on EtOH self-administration at 3 abstinence points: acute abstinence (A-Abst, 8 hours), late abstinence (L-Abst, 2 weeks), and protracted abstinence (P-Abst, 6 weeks). At each time point of abstinence, the rats were first scored for behavioral signs of withdrawal and then received oral NTX (10 mg/kg in a volume of 3 ml/kg; n = 6) or vehicle (VEH; water, n = 5/6 animals) administration. Sixty minutes later, they were placed in the operant chambers and allowed to self-administer 10% EtOH on an FR1 schedule for 30 minutes. NTX (or VEH) was administered according to a within-subjects design, such that the same group of rats received 3 NTX (or VEH) treatments: 1 at AAbst, 1 at L-Abst, and 1 at P-Abst.
It is known that the plasma concentration of NTX 60 minutes following an oral administration is~10 times lower when compared to the subcutaneous route (for comparison, see Ciccocioppo et al., 2003; Hussain et al. 1987) . The rationale for using a moderate 10 mg/kg oral dose of NTX was based on the literature and specifically on a recent study that reported a significant reduction of EtOH drinking in alcohol-preferring (P) rats following oral administration of 10 mg/kg NTX (Rorick-Kehn et al., 2014) . The oral bioavailability of NTX needs to be taken into account when comparing the present data with other studies that used other routes of administration (Ciccocioppo et al., 2003; Walker and Koob, 2008) .
Statistical Analysis
Two-way analysis of variance (ANOVA) was used to compare EtOH intake and inactive lever responses between males and females during the last 5 days of training. Two-way ANOVA was used to divide male and female rats into 2 subgroups to obtain a similar baseline (BSL) of EtOH intake based on the last 3 days of training pre-CIE vapor exposure. Two-way ANOVA was used to analyze differences in BALs between males and females that were caused by CIE vapor exposure. Three-way ANOVA was used to analyze differences in EtOH intake, inactive lever responses, BALs, and WDS during training and CIE vapor exposure between males and females. Three-way ANOVA was used to analyze differences in EtOH intake, inactive lever responses, BALs, and WDS related to NTX (or VEH) treatment at different time points of abstinence. Although WDS were measured prior to NTX and VEH treatment, the treatment factor (NTX vs. VEH) was retained as a variable to maintain the group subdivision at each abstinence point and consistency among the data presentation. When no significant 3-way interaction was found, 2-way ANOVA was used to analyze significant 2-way interactions. Significant effects in the ANOVAs were followed by Tukey's post hoc test. WDS values were transformed into log10 for statistical analysis and back-transformed for graphical representation. The results are expressed as mean AE SEM. Differences were considered significant at p < 0.05. The statistical analysis was performed using GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA) and Statistica 7.0 software (Dell Software, Roundrock, TX).
RESULTS
Two animals were excluded from the study, 1 in the male EtOH PD group and 1 in the female EtOH PD group, because they did not acquire EtOH self-administration, thus reducing the number of animals to 46 (n = 12 EtOH ND males and n = 11 EtOH PD males during training and CIE exposure; n = 6 EtOH ND males treated with NTX or VEH, n = 6 EtOH PD males treated with NTX, and n = 5 EtOH PD males treated with VEH; n = 12 EtOH ND females and n = 11 EtOH PD females during training and CIE procedure; and n = 6 EtOH ND females treated with NTX or VEH, n = 6 EtOH PD females treated with NTX, and n = 5 EtOH PD females treated with VEH).
EtOH Self-Administration Training
During the last 5 days of EtOH self-administration training (Fig. 2) , both groups of animals (males and females) presented stable and comparable EtOH intake in a 30-minute daily session, 2-way ANOVA: sex (male vs. female), F(1, 44) = 0.1, p > 0.05; time (days of self-administration), F(4, 176) = 1.3, p > 0.05; sex 9 time interaction, F(4, 176) = 1.1, p > 0.05. Responses at the inactive lever were low and constant across the last 5 days of training, 2-way ANOVA: sex (male vs. female), F(1, 44) = 5.8, p < 0.05; time (days of self-administration), F(4, 176) = 0.3, p > 0.05; sex 9 time interaction, F(4, 176) = 0.3, p > 0.05; Fig. 2 , bottom panel. The rats were then divided into 4 groups: EtOH ND males, EtOH PD males, EtOH ND females, and EtOH PD females.
EtOH Self-Administration During CIE Vapor Exposure
Before CIE or air exposure, male and female rats were divided into 2 subgroups to obtain a similar BSL of EtOH intake based on the last 3 days of training pre-CIE vapor exposure, BSL; 2-way ANOVA: sex (male vs. female), F(1, 42) = 0.04, p > 0.05; group (EtOH ND vs. EtOH PD ), F(1, 42) = 0.06, p > 0.05; sex 9 group interaction, F(1, 42) = 0.54, p > 0.05; Fig. 3A . At the end of CIE exposure (weeks 4 to 6), an increase in EtOH intake (calculated by averaging the measures that were obtained on Monday, Wednesday, and Friday of each week; Fig. 3A ) was detected in EtOH PD rats, with an overall difference between males and females, 3-way ANOVA: sex (male vs. female), F(1, 168) = 5.4, p < 0.05; group (EtOH ND vs. EtOH PD ), F(1, 168) = 98.2, p < 0.001; time (BSL, week 4, week 5, and week 6), F(3, 168) = 8.0, p < 0.001; sex 9 group 9 time interaction, F(3, 168) = 0.3, p > 0.05; Fig. 3A ,B. Although no significant 3-way interaction was detected, a significant 2-way group 9 time interaction was found, F(3, 168) = 11.8, p < 0.001. Separate 2-way ANOVAs by sex confirmed an increase in EtOH intake at weeks 4, 5, and 6 in males and females, males: group (EtOH ND vs. EtOH PD ), F(1, 21) = 36.2, p < 0.001; time (BSL, week 4, week 5, and week 6), F(3, 63) = 4.9, p < 0.01; group 9 time interaction, F(3, 63) = 19.7, p < 0.001; females: group (EtOH ND vs. EtOH PD ), F(1, 21) = 18.7, p < 0.05; time (BSL, week 4, week 5, and week 6), F(3, 63) = 7.0, p < 0.001; group 9 time interaction, F(3, 63) = 4.6, p < 0.01. Tukey's post hoc tests confirmed that EtOH PD rats drank significantly more EtOH from week 4 to week 6 of CIE vapor exposure (p < 0.001) vs. BSL and the EtOH ND group. Inactive lever responses remained low and unaffected in both males and females, 3-way ANOVA: sex (male vs. female), F(1, 168) = 24.7, p < 0.001; group (EtOH ND vs. EtOH PD ), F(1, 168) = 2.1, p > 0.05; time (BSL, week 4, week 5, and week 6), F(3, 168) = 2.4, p > 0.05; sex 9 group 9 time interaction, F(3, 168) = 0.2, p > 0.05; Fig. 3A .
Blood Alcohol Levels
During weeks 1, 2, and 3 of CIE exposure, the EtOH delivery was adjusted to reach and maintain an average BAL of 150 to 250 mg%. During weeks 4, 5, and 6 of CIE, BALs remained stable within the required range (150 to 250 mg%). Blood was collected once per week (on Thursdays; Fig. 1B ) 15 minutes before the EtOH vapor was turned off: week 4 (male: 171.9 AE 14.3 mg/100 ml; female: 154.0 AE 13.9 mg/100 ml), week 5 (male: 170.4 AE 22.6 mg/100 ml; female: 154.4 AE 8.8 mg/100 ml), and week 6 (male: 184.9 AE 18.9 mg/100 ml; female: 159.3 AE 6.0 mg/100 ml). No differences in BALs were found between males and females over the last 3 weeks of CIE vapor exposure, 2-way ANOVA: sex, F(1, 20) = 3.4, p > 0.05; time, F(2, 40) = 0.5, p > 0.05; sex 9 time interaction, F(2, 40) = 0.5, p > 0.05.
BALs that were measured after each self-administration session during the CIE vapor exposure were higher in EtOH PD rats (both males and females) compared with their respective pre-CIE vapor exposure (BSL). After self-administration, BALs were higher in EtOH PD animals versus EtOH ND for both sexes, with EtOH PD females having lower BALs than EtOH PD males across weeks 4, 5, and 6 of CIE Cumulative EtOH intake was higher in EtOH PD animals compared with EtOH ND animals and compared with the training condition in both males and females. Lower panel. Responses at the inactive lever remained low and stable in both sexes. (B) Blood alcohol levels (BALs) that were measured immediately after the self-administration session during CIE vapor exposure were higher in EtOH PD animals compared with EtOH ND animals in males and females, with females having lower BALs compared with males. (C) Somatic withdrawal signs (WDS) that were recorded prior to the EtOH self-administration sessions during CIE vapor exposure at 8 hours of abstinence were higher in EtOH PD animals than in EtOH ND animals in males and females, with females exhibiting higher WDS than males at weeks 4, 5, and 6 of CIE exposure. The y-axis for WDS is expressed as log10. vapor exposure, p < 0.05, Tukey's post hoc test following 3-way ANOVA: sex (male vs. female), F(1, 168) = 26.8, p < 0.001; group (EtOH ND vs. EtOH PD ), F(1, 168) = 261.3, p < 0.001; time (BSL, week 4, week 5, and week 6), F(3, 168) = 39.8, p < 0.001; sex 9 group 9 time interaction, F (3, 168) = 7.2, p < 0.001; Fig. 3B .
Withdrawal Scores
In males, during weeks 5 and 6 of CIE vapor exposure, WDS that were measured before the self-administration session were higher in EtOH PD animals compared with EtOH ND animals and compared with BSL. In females, WDS that were measured before the self-administration session were higher in EtOH PD animals compared with EtOH ND animals during weeks 4, 5, and 6 of CIE vapor exposure and compared with BSL. Compared with males, EtOH PD females exhibited significantly higher WDS, p < 0.05, Tukey's post hoc test following 3-way ANOVA: sex, F(1, 168) = 29.9, p < 0.001; group (EtOH ND and EtOH PD ), F(1, 168) = 57.6, p < 0.001; time (BSL, weeks 4, 5, and 6), F(3, 168) = 8.3, p < 0.001; sex 9 group 9 time interaction, F(3, 168) = 5.2, p < 0.05; Fig. 3C .
Effects of NTX on EtOH Self-Administration During Abstinence
EtOH Intake. Separate analyses of the differential behavioral effects of NTX across abstinence time points were performed between males and females. In males (Fig. 4A) , EtOH ND rats responded differently to NTX than EtOH PD rats over the different abstinence time points, 3-way ANOVA: time (A-Abst, L-Abst, P-Abst), F(2, 54) = 6.7, p < 0.01; treatment (VEH vs. NTX), F(1, 54) = 43.26, p < 0.001; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 32.17, p < 0.001; time 9 treatment 9 dependence interaction, F(2, 54) = 1.4, p > 0.05). No significant 3-way interaction was detected, but a significant 2-way time 9 treatment interaction was found, F(2, 54) = 4.6, p < 0.05. In EtOH ND males, the overall effect of NTX treatment was significant, 2-way ANOVA: treatment, F(1, 9) = 26.99, p < 0.001. In EtOH PD males, significant effects of time and NTX treatment were found, 2-way ANOVA: time, F(2, 18) = 9.6, p < 0.01; treatment, F(1, 9) = 6.0, p < 0.05. Tukey's post hoc tests confirmed that NTX reduced EtOH intake in EtOH ND rats at all abstinence time points (p < 0.05). In EtOH PD rats, NTX reduced EtOH intake only at P-Abst (p < 0.05). Inactive lever responses remained low and unaffected by NTX treatment, 3-way ANOVA: time (A-Abst, L-Abst, P-Abst), F(2, 54) = 1.7, p > 0.05; treatment (VEH vs. NTX), F(1, 54) = 0.2, p > 0.05; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 0.7, p > 0.05; time 9 treatment 9 dependence interaction, F(2, 54) = 0.4, p > 0.05; Fig. 4A .
In females (Fig. 5A) , NTX decreased EtOH intake in both the EtOH ND and the EtOH PD groups at all abstinence time points, 3-way ANOVA: time (A-Abst, L-Abst, P-Abst), F(2, 54) = 0.9, p > 0.05; treatment (VEH vs. NTX), F(1, 54) = 38.6, p < 0.001; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 22.5, p < 0.001; time 9 treatment 9 dependence interaction, F(2, 54) = 0.2, p > 0.05. No significant 3-way interaction was detected, but a significant 2-way treatment 9 dependence interaction was found, F(1, 54) = 4.6, p < 0.05. NTX reduced EtOH intake at A-Abst, 2-way ANOVA: treatment, F(1, 18) = 9.1, p < 0.05; dependence, F(1, 18) = 4.744, p < 0.05; treatment 9 dependence interaction, F(1, 18) = 0.4, p > 0.05, L-Abst, 2-way ANOVA: treatment, F(1, 18) = 16.3, p < 0.001; dependence, F(1, 18) = 13.1, p < 0.01; treatment 9 dependence interaction, F(1, 18) = 3.4, p > 0.05, and P-Abst, 2-way ANOVA: treatment, F(1, 18) = 16.9, p < 0.001; dependence, F(1, 18) = 9.3, p < 0.01; treatment 9 dependence interaction, F(1, 18) = 1.9, p > 0.05, in both EtOH ND and EtOH PD rats. Tukey's post hoc tests confirmed that NTX reduced EtOH intake in EtOH ND and EtOH PD rats at all abstinence time points (p < 0.05). Inactive lever responses remained low and unaffected, 3-way ANOVA: time (A-Abst, L-Abst, P-Abst), F(2, 54) = 0.9, p > 0.05; treatment (VEH vs. NTX), F(1, 54) = 1.1, p > 0.05; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 1.0, p > 0.05; time 9 treatment 9 dependence interaction, F(2, 54) = 0.3, p > 0.05; Fig. 5A .
Blood Alcohol Levels
In EtOH ND males, BALs after self-administration following NTX treatment at A-Abst, L-Abst, and P-Abst were lower compared with VEH-treated animals (p < 0.05, Tukey's post hoc test). In EtOH PD rats, lower BALs in NTX-treated animals versus VEH-treated animals were observed at L-Abst and P-Abst (p < 0.05, Tukey's post hoc test) but not at A-Abst, 3-way ANOVA: time (A-Abst, LAbst, P-Abst), F(2, 54) = 12.5, p < 0.001; treatment (VEH vs. NTX), F(1, 54) = 21.6, p < 0.001; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 101.4, p < 0.001; time 9 treatment 9 dependence interaction, F(2, 54) = 8.0, p < 0.001; Fig. 4B . EtOH ND rats exhibited lower BALs versus EtOH PD rats at A-Abst (p < 0.05, Tukey's post hoc test; Fig. 4B ).
In EtOH ND and EtOH PD females, BALs after self-administration following NTX treatment at A-Abst, L-Abst, and P-Abst were lower compared with VEH-treated animals, p < 0.05, Tukey's post hoc test following 3-way ANOVA: time (A-Abst, L-Abst, P-Abst), F(2, 54) = 3.23, p < 0.05; treatment (VEH vs. NTX), F(1, 54) = 38.9, p < 0.001; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 19.9, p < 0.001; time 9 treatment 9 dependence interaction, F(2, 54) = 6.5, p < 0.01; Fig. 5B .
Somatic Withdrawal Signs
In males (Fig. 4C) , overall effects of time of abstinence and dependence were found when scoring WDS, 3-way ANOVA: time (A-Abst, L-Abst, P-Abst), F(2, 54) = 9.4, p < 0.001; treatment (VEH vs. NTX), F(1, 54) = 0.2, p > 0.05; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 26.0, p < 0.001; time 9 treatment 9 dependence interaction, F(2, 54) = 0.1, p > 0.05. No significant 3-way interaction was detected, but a significant 2-way time 9 dependence interaction was found, F(2, 54) = 15.7, p < 0.001. EtOH PD rats had higher WDS scores compared with EtOH ND rats only at A-Abst in both VEH-treated animals, p < 0.01, Tukey's post hoc test following 2-way ANOVA: time, F(2, 18) = 7.7, p < 0.01; dependence, F(1, 9) = 20.2, p < 0.001; time 9 dependence interaction, F(2, 18) = 6.4, p < 0.05, and NTX-treated animals, p < 0.01, Tukey's post hoc test following 2-way ANOVA: time, F(2, 18) = 9.1, p < 0.01; dependence, F(1, 9) = 11.7, p < 0.01; time 9 dependence interaction, F(2, 18) = 6.2, p < 0.05. Further scrutiny of WDS scores between A-Abst and weeks 4 to 6 of CIE exposure suggested an increase in WDS scores at A-Abst, but this was not supported by the statistical analysis, 1-way ANOVA: F(4, 39) = 1.6, p > 0.05; Figs 3C and 4C).
In females (Fig. 5C ), similar to males, overall effects of time of abstinence and dependence were found when scoring WDS, 3-way ANOVA: time (A-Abst, L-Abst, P-Abst), F(2, 54) = 19.5, p < 0.001; treatment (VEH vs. NTX), F(1, 54) = 0.05, p > 0.05; dependence (EtOH ND vs. EtOH PD ), F(1, 54) = 28.5, p < 0.001; time 9 treatment 9 dependence interaction, F(2, 54) = 0.1, p > 0.05. No significant 3-way interaction was detected, but a significant 2-way time 9 dependence interaction was found, F(2, 54) = 6.9, p < 0.01. EtOH PD rats had higher WDS scores compared with EtOH ND rats at A-Abst and L-Abst, whereas no difference in WDS scores was observed at P-Abst between ETOH ND and EtOH PD rats in both VEH-treated animals, p < 0.05, Tukey's post hoc test following 2-way ANOVA: time, F(2, 18) = 11.5, p < 0.01; dependence, F(1, 9) = 18.2, p < 0.01; time 9 dependence interaction, F(2, 18) = 4.8, p < 0.05, and NTX-treated animals, p < 0.05, Tukey's post hoc test following 2-way ANOVA: time, F(2, 18) = 14.6, p < 0.001; dependence, F(1, 9) = 5.7, p < 0.05; time 9 dependence interaction, F(2, 18) = 3.9, p < 0.05. Further scrutiny of WDS scores between A-Abst and weeks 4 to 6 of CIE exposure suggested an increase in WDS scores at A-Abst, but this was not supported by the statistical analysis, 1-way ANOVA: F(4, 39) = 1.6, p > 0.05; Figs 3C and 5C.
DISCUSSION
One characteristic of AUD in humans is that dependent subjects will consume EtOH to relieve or avoid withdrawal symptoms (Peer et al., 2013) . Similarly, in preclinical studies, EtOH postdependent rats exhibit an EtOH dependence syndrome that is characterized by both somatic and motivational withdrawal symptoms that usually begin after 6 to 8 hours of abstinence and engage in excessive drinking when EtOH is made available again (Roberts et al., 1996; Vendruscolo and Roberts, 2014) . The present study strongly supported the validity of the CIE vapor exposure model as a valid procedure to induce and study EtOH dependence in both male and female rats. Indeed, EtOH PD rats exhibited an enhancement (i.e., escalation) of EtOH drinking during dependence (week 4 to week 6), suggesting a transition from controlled to excessive EtOH intake, most likely in an effort to alleviate negative withdrawal states (for review, see Koob 2014) . These behavioral changes are characteristic of dependence and reflect neuroadaptive changes that are induced by CIE that in turn disrupt brain function (e.g., reward), physiological processes, and cognitive processes (Becker and Mulholland, 2014; Koob, 2008) and could account for the changes in the efficacy of NTX in reducing EtOH drinking in the present study.
Although an overall significant effect of sex on EtOH drinking was observed during CIE vapor exposure (Fig. 3A) , the possible increase in EtOH intake in females from week 4 to week 6 (suggested by further scrutiny of Fig. 3A) was not confirmed statistically. However, compared with females, males had higher BALs (Fig. 3B ) and significantly lower WDS scores at weeks 4, 5, and 6 of CIE vapor exposure (Fig. 3C) . The EtOH intake that was observed in males and females is difficult to reconcile with previous studies that reported a range of contradictory results. Several studies reported sex differences in EtOH intake, in which female rats drank more than males (Blanchard et al., 1993; Li and Lumeng, 1984; Morales et al., 2015; , whereas other studies found no differences (van Haaren and Anderson, 1994; Moore and Lynch, 2015; Schramm-Sapyta et al., 2014) . The use of different strains (e.g., Wistar, Sprague Dawley, and Long Evans) or different experimental designs (e.g., 2-bottle choice, self-administration, and CIE vapor exposure) may account for such discrepancies. For example, female Long Evans and Wistar rats consumed more EtOH than their male counterparts when given either continuous or intermittent access to EtOH in their home cages (Priddy et al., 2017) . Under operant conditions, no sex or strain differences were found in drinking prior to the development of EtOH dependence (Priddy et al., 2017) . Consistent with the present results, upon dependence induction by CIE exposure, Wistar rats of both sexes substantially escalated their EtOH intake compared with their nondependent drinking levels, whereas Long Evans rats only exhibited a moderate escalation of drinking, without showing any sex difference (Priddy et al., 2017) . Thus, strain, sex, and drinking condition may interact to modulate EtOH drinking and are important factors to consider when exploring individual differences in EtOH drinking and dependence.
BALs following EtOH self-administration at weeks 4 to 6 of CIE vapor exposure were higher in males than in females (Fig. 3B) . Biological (sex-related) factors, including differences in EtOH metabolism (for review, see Cederbaum 2012) and its effect on brain function and the levels of sex hormones, may contribute to some of these differences. For example, male and female mice differed in their sensitivity to changes in c-aminobutyric acid-ergic neurosteroid levels with regard to EtOH exposure (Finn et al., 2010) and an interactive effect of sex and chronic EtOH consumption on blood glucose homeostasis was observed in Wistar rats (Sumida et al., 2004) . Another explanation for such differences is that females may have failed to drink the EtOH that was dispensed compared with males. Dependent females exhibited the same EtOH intake at week 6 of CIE and at AAbst after VEH treatment, but they had different BALs after the self-administration sessions. This discrepancy is difficult to explain. One possibility could be that females metabolize EtOH differently across the estrous cycle. For example, mesocortical dopaminergic pathways are differentially sensitive to acute EtOH administration across the estrous cycle (Dazzi et al., 2007) . Additionally, as mentioned above, an alternative explanation could be that females simply did not actually drink the EtOH that was delivered at A-Abst. Females not only had lower BALs than males, but also had higher WDS scores than males (Fig. 3C) . These results are difficult to reconcile with previous studies that usually reported an increase in WDS in males but not in females (for review, see Becker and Koob 2016) . However, several studies showed that females may be more sensitive to the degenerative effects of EtOH dependence (i.e., brain area volume reductions), and women seek treatment earlier in their drinking history than males (for review, see Sharrett-Field et al. 2013 ), strongly suggesting a differential effect of chronic EtOH exposure in females versus males. One explanation for the greater severity of WDS in females in the present study could be the experimental design (i.e., the duration of CIE vapor exposure to which females may be more sensitive). The observation that EtOH ND females had WDS scores that were comparable to EtOH PD males was also unexpected but may have resulted from increases in stress or anxiety responses in females (for review, see Bangasser and Valentino 2014) . For example, vocalization, one of the WDS measures that was scored, is a known stress response and could have accounted for an overall higher WDS score in EtOH ND females (Meyer, 2015) . Such a possibility, however, requires further investigation.
The neurobiological basis for sex differences in AUD is largely unknown, partially because most studies of EtOH drinking are conducted only in males. Gender differences in responses to AUD treatments are currently considered clinically, but the number of female subjects is usually limited and not always sufficient to establish the efficacy of treatment (Agabio et al., 2016) . The present results showed that both male and female Wistar rats acquired EtOH self-administration and consumed the same amount of EtOH during the training phase. During the final 3 weeks of the CIE procedure (week 4 to week 6), both males and females exhibited significant escalation of EtOH intake compared with their respective air-exposed control groups. However, males and females responded differently to NTX. In EtOH ND animals (both males and females), NTX significantly reduced EtOH intake at all abstinence time points (A-Abst, L-Abst, and PAbst), and a significant change in the efficacy of NTX was observed in EtOH PD . NTX was effective in EtOH PD males only at P-Abst but reduced EtOH drinking in EtOH PD females at all 3 abstinence time points.
Nondependent males and nondependent and postdependent females presented a NTX-induced decrease in EtOH drinking, regardless of the duration of abstinence. However, postdependent males were responsive to NTX after a longer period of abstinence. This variability in the efficacy of NTX is consistent with earlier studies that showed that NTX suppressed EtOH consumption in nondependent subjects Gonzales and Weiss, 1998; Shoemaker et al., 2002; Stromberg, 2004) , and this effect was blunted in postdependent subjects (Ji et al., 2008; Sabino et al., 2006 Sabino et al., , 2013 Walker and Koob, 2008) . The efficacy of NTX in reducing EtOH intake may be affected by several factors, such as the model that is used (e.g., 2-bottle choice vs. self-administration), the duration of EtOH self-administration, the severity of dependence, timing of the pharmacological intervention, sex, and changes in the endogenous opioid system. For example, acute NTX administration suppressed binge drinking in rats (Ji et al., 2008) , and NTX was also highly effective in nondependent rats that were selectively bred for high alcohol preference (Sardinian alcohol-preferring [sP] rats; Sabino et al. 2006) . The lack of an effect of NTX at A-Abst in males was surprising when considering an earlier study by Walker and Koob (2008) that showed that a subcutaneous injection of NTX at lower doses than the one that was used in the present study reduced EtOH self-administration in nondependent and postdependent animals during A-Abst (Walker and Koob, 2008) . One tentative explanation for this discrepant finding could be the lower bioavailability of NTX following oral administration (e.g., Hussain et al. 1987) . Chronic NTX administration blocked the increase in EtOH consumption after a 5-day period of forced abstinence (Heyser et al., 2003) . Changes in the endogenous opioid system are observed in response to chronic exposure to EtOH and after its removal, and these changes may be responsible for the effect of NTX or lack thereof. For example, chronic EtOH administration has been reported to increase activity of the hypothalamic b-endorphin system (Angelogianni and Gianoulakis, 1993; Schulz et al., 1980) , cause no change (Seizinger et al., 1983) , or even decrease activity (Scanlon et al., 1992) . One hypothesis could be that the greater b-endorphin release that is induced by acute exposure to EtOH induces drinking, whereas a decrease in b-endorphin activity that is induced by chronic EtOH intake may promote and maintain EtOH consumption because of negative reinforcement rather than positive reinforcement. However, the reason why NTX was ineffective in postdependent males at A-Abst and L-Abst in the present study is unclear and will need further exploration.
One tentative explanation for the differential effect of NTX between males and females may be differential changes in the endogenous opioid system in response to chronic EtOH. Overall, acute EtOH has been shown to stimulate the release of b-endorphin, enkephalins, and dynorphin in humans and rats (Dai et al., 2005; Gianoulakis et al., 1996a; Marinelli et al., 2003 Marinelli et al., , 2005 Marinelli et al., , 2006 . Chronic EtOH exposure induced changes in opioid peptide systems that involve alterations at the levels of the peptides themselves (Gianoulakis et al., 1996b; Lindholm et al., 2000) , changes in receptor densities and effector systems (Chen and Lawrence, 2000; Turchan et al., 1999) , and modifications of mRNA that encode both opioid peptides and receptors (Przewlocka et al., 1997; Rosin et al., 1999) . Therefore, the differential effects of NTX in males and females may reflect sexual dimorphism of the endogenous opioid system and different effects of chronic EtOH use in males and females. Sexual dimorphism in the endogenous opioid system has been described in the control of pain. For example, variable responses to the analgesic effects of opioids have been attributable to sex (Dahan et al., 2008) , but the mechanisms that underlie sex differences in opioid analgesia remain elusive. Sex differences in opioid analgesia are also not likely related to differences in opioid receptor density because no differences were found between male and female rats in brain lor d-opioid receptor populations (Kepler et al., 1991) . In humans, nonselective j and l ligands have been reported to produce stronger analgesic effects in women than in men (Rasakham and Liu-Chen, 2011) . In animals, selective j receptor agonists have been found to produce greater antinociceptive effects in males than in females (Rasakham and Liu-Chen, 2011 ). These observations suggest that the extent of sex differences in j-, l-, and d-mediated analgesia is related to species, strain, ligand, and pain model. For example, the selective j-opioid receptor agonist spiradoline was more potent in female than in male Wistar rats in the tail withdrawal test (Terner et al., 2003) . The exact nature of the changes in the endogenous opioid system during EtOH dependence and withdrawal that may explain the higher sensitivity to NTX in EtOH PD females remains to be established.
Clinical studies have shown that NTX treatment is more effective in patients who continue to drink EtOH during the course of treatment (Heinala et al., 2001; Killeen et al., 2004) . One could argue that the efficacy of NTX treatment at P-Abst in EtOH PD males was the result of prior exposure to NTX with EtOH during the earlier tests (A-Abst and LAbst). Therefore, in contrast to females, repeated NTX dosing in EtOH PD males may be necessary to elicit efficacy and thus be independent of the time of abstinence. Another explanation for the NTX-induced decrease in EtOH drinking could be related to an interaction between NTX and the palatability (taste) of EtOH. Supporting this hypothesis, previous studies found that NTX induced a conditioned taste aversion to EtOH in rats, monkeys, and humans, and to palatable food and sweet solutions (Beczkowska et al., 1992; Coonfield et al., 2002; Ferraro et al., 2002; Mitchell et al., 2009; Stromberg et al., 2002; Williams and Woods, 1999a,b) , consequently reducing EtOH intake. Sex differences in the palatability of EtOH could also contribute to the differential effect of NTX in reducing EtOH intake in EtOH PD rats. For example, women have been found to be more sensitive to the aversive effects of NTX (Agabio et al., 2016; Garbutt et al., 2005; O'Malley et al., 2007) . Therefore, one can argue that the treatment efficacy of NTX in the present study might be correlated with the level of NTX-induced aversive side effects (Mitchell et al., 2009 ).
In conclusion, the present results further support targeting the endogenous opioid system to prevent excessive drinking that is characteristic of AUD, even after long periods of abstinence. The present study extends our knowledge of the efficacy of NTX treatment by showing that it varies between sexes and different time points of abstinence. This could explain some of the contradictory findings that described various effects or lack of effects of NTX in some cases (Bell and Reisine, 1993; Kakidani et al., 1982) . In males, NTX was ineffective in reducing EtOH drinking during A-Abst, whereas NTX decreased EtOH drinking at A-Abst, L-Abst, and P-Abst in females. These findings suggest that NTX might modulate long-lasting craving-induced EtOH drinking in males and not acute EtOH withdrawal-induced (e.g., corticotropin-releasing factor-induced) EtOH drinking (Koob, 2015) . This hypothesis will need further investigation. Overall, the present study has important implications because it points toward individual differences in the endogenous opioid system that should be considered when developing new pharmacotherapies to treat AUD.
